On July 17, Oruka Therapeutics rose 9.43% in regular trading, trading at approximately $91.14/share, with turnover of $120 million. The rally was driven by renewed market optimism surrounding the company's upcoming second-half clinical data readouts for its lead psoriasis candidate, ORKA-001.

On the news front, UBS Securities issued a research note highlighting that H2 data could further de-risk Oruka's lead program, projecting that the 28-week PASI100 response rate will improve from approximately 63% at week 16 to 70%-80%, potentially outperforming AbbVie's Skyrizi. UBS also noted that AbbVie's planned acquisition of Apogee Therapeutics validates the underlying YTE platform technology that Oruka leverages. Initial one-year durability data are expected in late Q3 or Q4, which could provide early evidence of ORKA-001's potential for six-month or annual dosing intervals. Oruka reported positive Phase 2a results in April showing 63.5% complete skin clearance at week 16 and 83% achieving PASI 90, and subsequently completed a $700 million public offering to fund continued development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)